Background: Many elderly men with high-risk nonmetastatic prostate cancer (HRnMPCa) do not receive radical treatment, despite the high mortality associated with conservative management. Objective: To investigate how age and comorbidity affect treatment of men with HRnMPCa. Design, setting, and participants: This was an observational nationwide register study during 2001-2012. We identified 19 190 men of <80 yr of age diagnosed with HRnMPCa in the National Prostate Cancer Register of Sweden and 95 948 age-matched men without prostate cancer in the register of the total population. Outcome measurements and statistical analysis: The outcome was the proportion of men with HRnMPCa receiving radical treatment (radical prostatectomy or radiothe...
IMPORTANCE: The long-term outcomes among men with prostate cancer (PC) whose disease is managed with...
Purpose We compared clinical characteristics and cancer specific mortality in men diagnosed with pro...
Purpose: Few studies have evaluated the prime treatment choice for men older than 80 years with acut...
Background: Many elderly men with high-risk nonmetastatic prostate cancer (HRnMPCa) do not receive r...
AbstractBackgroundMany elderly men with high-risk nonmetastatic prostate cancer (HRnMPCa) do not rec...
Background: Elderly patients diagnosed with high-risk prostate cancer (PCa) present a therapeutic di...
Tailored treatment with adequate timing is essential for the quality of prostate cancer care at all ...
Based on the exponential aging of the population and the increasing life expectancy in industrialize...
It’s the most common cancer among men. Prostate cancer will affect one in five men at some point in ...
Abstract Treatment guidelines recommend that curative radiation treatment of prostate cancer be offe...
Objectives. The life expectancy of candidates for attempted curative therapy of prostate cancer shou...
Elderly men are more likely to be diagnosed with aggressive cancer, but are often inappropriately de...
Objectives: To examine the clinical features, applied treatments, and survival of older patients wit...
Given the demographic trends toward a considerably longer life expectancy, the percentage of elderly...
Context: The appropriate therapy for men with clinically localized prostate cancer is uncertain. A r...
IMPORTANCE: The long-term outcomes among men with prostate cancer (PC) whose disease is managed with...
Purpose We compared clinical characteristics and cancer specific mortality in men diagnosed with pro...
Purpose: Few studies have evaluated the prime treatment choice for men older than 80 years with acut...
Background: Many elderly men with high-risk nonmetastatic prostate cancer (HRnMPCa) do not receive r...
AbstractBackgroundMany elderly men with high-risk nonmetastatic prostate cancer (HRnMPCa) do not rec...
Background: Elderly patients diagnosed with high-risk prostate cancer (PCa) present a therapeutic di...
Tailored treatment with adequate timing is essential for the quality of prostate cancer care at all ...
Based on the exponential aging of the population and the increasing life expectancy in industrialize...
It’s the most common cancer among men. Prostate cancer will affect one in five men at some point in ...
Abstract Treatment guidelines recommend that curative radiation treatment of prostate cancer be offe...
Objectives. The life expectancy of candidates for attempted curative therapy of prostate cancer shou...
Elderly men are more likely to be diagnosed with aggressive cancer, but are often inappropriately de...
Objectives: To examine the clinical features, applied treatments, and survival of older patients wit...
Given the demographic trends toward a considerably longer life expectancy, the percentage of elderly...
Context: The appropriate therapy for men with clinically localized prostate cancer is uncertain. A r...
IMPORTANCE: The long-term outcomes among men with prostate cancer (PC) whose disease is managed with...
Purpose We compared clinical characteristics and cancer specific mortality in men diagnosed with pro...
Purpose: Few studies have evaluated the prime treatment choice for men older than 80 years with acut...